On Monday, the FDA approved aducanumab, a new medication for Alzheimer’s.
It’s the first new drug for the disease in almost two decades and the first to attack the disease process itself, instead of just its symptoms.
But the FDA’s approval comes despite an intense debate over the drug’s efficacy and associated side effects.
From Kaiser Health News:
We discuss what we know about aducanumab and how it will shape the future of Alzheimer’s research and treatment.
Copyright 2021 WAMU 88.5